Physician profile
Henry Su
NPI 1568493831
$2,812.07
in general payments reported to CMS, 2019-2025
23 companies · $40.54 in 2025
The $40.54 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $462 · 2021: $504 · 2022: $477 · 2023: $302 · 2024: $20.47 · 2025: $40.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.36 | 2019-2023 | Lo Loestrin Fe |
| Daiichi Sankyo INC. | $389.86 | 2019-2022 | |
| Lupin INC. | $327.70 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $301.85 | 2021-2023 | |
| Roche Diagnostics Corporation | $165.33 | 2019-2020 | |
| Evofem Biosciences, INC. | $149.14 | 2021-2025 | Phexxi, Solosec, Phexx |
| Bayer Healthcare Pharmaceuticals INC. | $133.08 | 2019-2020 | |
| Hologic Sales and Service, LLC | $131.60 | 2019-2023 | Affirm Prone Biopsy System |
| Smith+Nephew, INC. | $118.35 | 2019 | |
| Avion Pharmaceuticals | $106.02 | 2022-2023 | Balcoltra |
| Allergan, INC. | $73.20 | 2019-2020 | |
| Covidien Lp | $55.58 | 2019 | |
| Coopersurgical, INC. | $49.67 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.58 | 2019-2020 | |
| Optumhealth Care Solutions, LLC | $43.14 | 2023 | Zyno Solutions, Vivify Health Care Team Portal |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $28.08 | 2021-2022 | |
| Becton, Dickinson and Company | $27.40 | 2019 | |
| Sumitomo Pharma America, INC. | $24.45 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $23.02 | 2019 | |
| Aspira Women'S Health INC | $22.40 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $19.06 | 2022 | |
| Astellas Pharma US INC | $16.73 | 2023 | Veozah |
| Mylan Pharmaceuticals INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.